BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Igata Y, Kudo M, Kojima M, Kami S, Aoki K, Satake T, Kobayashi T, Sugimoto M, Kobayashi S, Konishi M, Gotohda N. Conversion surgery after gemcitabine and cisplatin plus durvalumab for advanced intrahepatic cholangiocarcinoma: A case report. World J Clin Cases 2024; 12(34): 6721-6727 [PMID: 39650816 DOI: 10.12998/wjcc.v12.i34.6721]
URL: https://www.wjgnet.com/2307-8960/full/v12/i34/6721.htm
Number Citing Articles
1
Koshiro Fukuda, Akiyoshi Kasuga, Yasuyuki Shigematsu, Kenichiro Kato, Hiromichi Ito, Arisa Ueki, Takeshi Okamoto, Masato Ozaka, Yu Takahashi, Naoki Sasahira. Pathological complete response following addition of durvalumab to gemcitabine and cisplatin therapy for intrahepatic cholangiocarcinoma with Lynch syndrome-associated mismatch repair deficiencyClinical Journal of Gastroenterology 2025; 18(3) doi: 10.1007/s12328-025-02122-1
2
Zun-Yi Zhang, Zhi-Yong Huang, Tong Yuan, Mi Zhou, Jun-Jie Liu. Conversion treatment for advanced intrahepatic cholangiocarcinoma: Opportunities and challengesWorld Journal of Gastroenterology 2025; 31(15): 104901 doi: 10.3748/wjg.v31.i15.104901
3
Shinichiro Hasegawa, Hiroshi Wada, Ryoji Takada, Masahiko Kubo, Masahiro Umezu, Shigenori Nagata, Keiichiro Honma, Yasunari Fukuda, Hisateru Komatsu, Kunihito Gotoh, Kei Yamamoto, Ryota Mori, Masatoshi Kitakaze, Norihiro Matsuura, Yasunori Masuike, Takahito Sugase, Yuki Ushimaru, Masaaki Miyo, Yoshitomo Yanagimoto, Takashi Kanemura, Toshinori Sueda, Yoshinori Kagawa, Kazuyoshi Yamamoto, Junichi Nishimura, Hiroshi Miyata, Masayuki Ohue, Shogo Kobayashi. Immunotherapy‐Facilitated Conversion Surgery for Biliary Tract Cancer: A Case Series of Long‐Term Survivors Following Durvalumab Combined With Gemcitabine and CisplatinHepatology Research 2026;  doi: 10.1111/hepr.70210
4
雨 马. Research Advances in the Molecular Mechanisms and Treatment of Intrahepatic CholangiocarcinomaWorld Journal of Cancer Research 2026; 16(02) doi: 10.12677/wjcr.2026.162009